101. Holmium laser enucleation and water vapor thermal therapy for the treatment of symptomatic benign prostatic hyperplasia: A cost analysis
- Author
-
F. Bottet, C. Eghazarian, C. Alegorides, A. Atamian, F. Arroua, Marc Fourmarier, and Michael Baboudjian
- Subjects
Male ,medicine.medical_specialty ,Urology ,Enucleation ,Prostatic Hyperplasia ,030232 urology & nephrology ,Holmium laser ,Thermal therapy ,Lasers, Solid-State ,03 medical and health sciences ,0302 clinical medicine ,Prostate ,Lower urinary tract symptoms ,medicine ,Humans ,business.industry ,Gold standard ,Transurethral Resection of Prostate ,Hyperplasia ,medicine.disease ,Surgery ,Steam ,Treatment Outcome ,medicine.anatomical_structure ,Costs and Cost Analysis ,Cost analysis ,Laser Therapy ,business - Abstract
PURPOSE To perform a cost analysis of the current gold standard operation of Holmium Laser Enucleation of the prostate (HoLEP) compared to the new technique of water vapor thermal therapy with the Rezum™ system for the treatment of symptomatic benign prostatic hyperplasia (BPH). PATIENTS AND METHODS Between October 2017 and January 2020, consecutive patients with invalidating lower urinary tract symptoms due to BPH who underwent Rezūm™ and HoLEP procedures from the Aix regional hospital were identified. The outcome of each technique was assessed in terms of cost from the institutional perspective. Detailed expense reports based were provided by the accounts department of the hospital. These were used to compare in-hospital costs for each procedure. RESULTS A total of 53 and 94 consecutive patients underwent respectively water vapor thermal therapy and HoLEP. The median costs for the surgical procedure were €1344 (IQR 1331-1361) and €669 (IQR 584-824), respectively for Rezūm™ and HoLEP (median difference €675; P
- Published
- 2022